<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97331">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743157</url>
  </required_header>
  <id_info>
    <org_study_id>BBI Total Therapy</org_study_id>
    <nct_id>NCT01743157</nct_id>
  </id_info>
  <brief_title>Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma</brief_title>
  <acronym>BBI</acronym>
  <official_title>A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I-II study of treatment of metastatic melanoma using induction therapy with
      Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I-II study of treatment of metastatic melanoma using induction therapy with
      Biochemotherapy (Temodar,Cisplatin, Velban,IL2 and IFN)plus Bevacizumab followed by
      consolidation therapy with Ipilimumab (BBI)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)</measure>
    <time_frame>Primary Objective</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the incidence of grade 4 bevacizumab-related toxicities and grade 3 proteinuria when bevacizumab is given with biochemotherapy to patients with metastatic melanoma for up to 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)</measure>
    <time_frame>Secondary Objective</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare median and overall progression-free survival to previously published historical control group of 135 patients receiving biochemotherapy followed by pulse IL-2, and also patients in the study of Weber et al (Reference 9) of ipilimumab in previously untreated patients for up to 4 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Biochemo + Bevacizumab then Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm:  Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochemo + bevacizumab then ipilimumab</intervention_name>
    <description>Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, &amp; 4)</description>
    <arm_group_label>Biochemo + Bevacizumab then Ipilimumab</arm_group_label>
    <other_name>Avastin,</other_name>
    <other_name>Temodar,</other_name>
    <other_name>Platinol,</other_name>
    <other_name>Velban,</other_name>
    <other_name>interleukin-2,</other_name>
    <other_name>Intron-A,</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable
             disease

          2. Age 18-70 years old

          3. Adequate pulmonary and cardiac function for high-dose IL-2

          4. PS 0-2

          5. Previous ipilimumab therapy will not exclude patients, but patients with previous
             ipilimumab will have separate efficacy analysis

        Exclusion Criteria:

          1. Brain metastases

          2. Creatinine &gt; 2x ULN; bilirubin &gt; 3, WBC &lt; 3500, Platelets &lt; 100,000, Hgb &lt; 9

          3. Another active malignancy

          4. Gastrointestinal tract metastases except rectal metastases or primary are allowable

          5. Previous therapy for metastatic disease with chemotherapy of duration over 3  months
             or with high-dose interleukin-2

          6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis

          7. Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding,
             uncontrolled hypertension, proteinuria with protein/creatinine ratio &gt; 1, acute
             myocardial infarction within 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Minor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 28, 2013</lastchanged_date>
  <firstreceived_date>April 4, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Pacific Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>David Minor, MD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>Yes</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
